Fargo, NDNCT04966481Now EnrollingIRB Ready

Head and Neck Cancer Clinical Trial in Fargo, ND

Access cutting-edge head and neck cancer treatment through this phase 3 clinical trial at a research site in Fargo. Study-provided care at no cost to qualified participants.

Sponsored by Washington University School of Medicine

Quick Self-Assessment

See if you qualify for this Fargo location

Preparing your pre-screening questions…

Expert Care in Fargo

Access head and neck cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related head and neck cancer treatment provided free

Apply for This Fargo Location

Check if you qualify for this head and neck cancer clinical trial in Fargo, ND

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Fargo

    Convenient for ND residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Fargo site if eligible
  4. 4Begin participation

About This Head and Neck Cancer Study in Fargo

This multicenter, open-label, randomized phase 3 trial will determine if palbociclib and cetuximab (Arm 1) improves overall survival (OS) in comparison to cetuximab monotherapy (Arm 2) in patients with CDKN2A-altered, HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who experienced disease progression on a PD-1/L1 inhibitor (given as monotherapy or in combination with other therapy).

Sponsor: Washington University School of Medicine

Who Can Participate

Inclusion Criteria

Histologically or cytologically confirmed RM-HNSCC that is HPV-unrelated disease; defined as SCC of the oral cavity, larynx, or hypopharynx and p16 negative SCC of the oropharynx or p16 negative non-cutaneous SCC unknown primary of the neck.
CDKN2A loss-of-function (LOF) alteration: mutation or homozygous deletion described on genomic sequencing report.
Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with CT scan, as ≥ 20 mm by chest x-ray, or ≥ 10 mm with calipers by clinical exam, per RECIST 1.1.
Disease progression on a PD-1/L1 inhibitor-containing regimen (given as monotherapy or in combination with other therapy).
Received no more than three lines of prior therapy for RM-HNSCC.
At least 18 years of age.
ECOG performance status ≤ 1.
Normal bone marrow and organ function as defined below:
Hemoglobin ≥ 8 g/L
Absolute neutrophil count ≥ 1,000/mcl
Platelets ≥ 100,000/mcl
Total bilirubin ≤ 3 x institutional upper limit of normal (IULN)
AST(SGOT)/ALT(SGPT) ≤ 5 x IULN (for cases involving liver metastases, AST/ALT ≤ 10 x IULN)
Serum creatinine \< 3 x IULN or creatinine clearance \> 30 mL/min by Cockcroft-Gault
The effects of palbociclib and cetuximab on the developing human fetus are unknown. For this reason and because CDK 4/6 inhibitors are known to be teratogenic, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and 3 months days after completion of the study
Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria

Prior treatment with cetuximab for recurrent or metastatic disease (however, prior cetuximab given as a component of multimodality therapy for newly diagnosed, locally advanced, non-metastatic HNSCC is allowable).
Prior treatment with a CDK4/6 inhibitor for RM-HNSCC.
Rb (retinoblastoma) loss: mutation or homozygous deletion described on genomic sequencing report.
Currently receiving any other investigational agents.
A history of other malignancy with the exception of malignancies for which all treatment was completed at least 1 year before registration and the patient has no evidence of recurrent/persistent disease.
Patients with treated brain metastases are eligible if there is no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib or other agents used in the study (excluding cetuximab).
Prior grade 3 or 4 (per CTCAE 5.0) hypersensitivity reaction to cetuximab.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
QTc \>500 msec (using Bazette formula).
Patients with HIV are eligible unless their CD4+ T-cell counts are \< 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended. Recommend exclusion of specific ART agents based on predicted drug-drug interactions (i.e. for sensitive CYP3A4 substrates, concurrent strong CYP3A4 inhibitors (ritonavir and cobicistat) or inducers (efavirenz) should be contraindicated).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fargo?

Yes, this clinical trial (NCT04966481) has an active research site in Fargo, ND that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Head and Neck Cancer Treatment Options in Fargo, ND

If you're searching for head and neck cancer treatment options in Fargo, ND, this clinical trial (NCT04966481) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fargo research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced head and neck cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all head and neck cancer clinical trials near you to find additional studies recruiting in your area.

More Head and Neck Cancer Trials in Fargo, ND

See all head and neck cancer clinical trials recruiting in Fargo — not just this study.

Browse Head and Neck Cancer Trials in Fargo →

Browse More Trials by Condition

Head and Neck Cancer TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in Fargo?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Fargo, ND